What is Marginal Zone Lymphoma?
Marginal zone lymphoma (MZL) is an indolent B-cell non-Hodgkin lymphoma arising from marginal zone B cells within lymphoid follicles, representing approximately 5-15% of all non-Hodgkin lymphomas in the Western world 1.
Classification and Subtypes
MZL encompasses three distinct anatomical subtypes, each with unique clinical characteristics:
Extranodal MZL (EMZL): Comprises approximately two-thirds of all MZL cases. Also known as MALT (mucosa-associated lymphoid tissue) lymphoma, it can arise at any extranodal site. The stomach is the most common location, followed by ocular adnexa, lung, and salivary glands 1.
Splenic MZL (SMZL): Accounts for approximately 20% of MZL cases 1.
Nodal MZL (NMZL): Represents less than 10% of cases 1.
Pathogenesis and Etiology
A defining feature of MZL is its frequent association with chronic antigenic stimulation from infections or autoimmune disorders 1. The disease typically develops in the context of:
- Chronic infections (Helicobacter pylori in gastric EMZL, hepatitis C virus, Campylobacter jejuni, Chlamydia psittaci, Borrelia burgdorferi)
- Autoimmune conditions
- Persistent inflammatory states
This chronic stimulation promotes ectopic lymphoid tissue development and sustained B-cell activation, eventually leading to lymphomagenesis through additional oncogenic events 2.
Morphology and Immunophenotype
Cellular Characteristics
The typical marginal zone B cells are small- to medium-sized with:
- Slightly irregular nuclei
- Inconspicuous nucleoli
- Moderately dispersed chromatin
- Pale cytoplasm (may appear monocytoid) 1
Diagnostic Immunohistochemistry
Diagnosis requires immunohistochemistry with at least CD20, CD10, CD5, CD23, cyclin D1, immunoglobulin D, and SOX-11 1. The characteristic immunophenotype is:
- CD20: Positive (mandatory)
- CD5: Negative (mandatory)
- CD10: Negative (mandatory)
- Cyclin D1: Negative (mandatory)
- CD23: Variable
- MYD88 mutation: Typically negative 1
Critical Diagnostic Caveat
All diagnostic and follow-up biopsies should be reviewed by an expert hematopathologist 1. Transformation to large B-cell lymphoma is diagnosed when clearly separated sheets of large cells comprise more than 20% of the neoplastic population 1.
Clinical Behavior
MZL is characterized by:
- Indolent clinical course in most cases
- Heterogeneous behavior depending on anatomical site and molecular characteristics
- Potential for transformation to aggressive lymphoma (though uncommon)
- Site-specific progression patterns influenced by genetic and geographical factors 1
Key Distinguishing Features by Subtype
EMZL Specifics
- Lymphoepithelial lesions are neither essential nor absolutely specific for diagnosis 1
- In gastric cases, H. pylori status must be confirmed by histochemistry, serology, urea breath test, or stool antigen test 1
- FISH for t(11;18)(p21;p21) helps identify patients unlikely to respond to antibiotic therapy 1
SMZL Specifics
- Can often be diagnosed without splenectomy using peripheral blood/bone marrow morphology, flow cytometry, and bone marrow biopsy 1
- Neoplastic lymphocytes may display villi (though not always present or visible) 1
NMZL Specifics
- Shares morphological and immunophenotypic similarities with other MZL subtypes but requires differentiation from other indolent lymphomas 1